Currently, guideline for the risk stratification of AML had included cytogenetic abnormalities, as well as gene mutations in NPM1, CEBPA, FLT3, and KIT (Dohner et al., 2017), improving the diagnosis and prognosis of AML patients. The gene discussed is CEBPA; the disease is acute myeloid leukemia.